#Sweden #AGM #Stockholm #BioArctic #Nasdaq Stockholm

Highlights from BioArctic AB's Annual General Meeting

BioArctic AB (publ), listed on Nasdaq Stockholm as BIOA B, conducted its Annual General Meeting (AGM) on May 28, 2026, in Stockholm. During this significant event, several key resolutions were reached, marking essential directives for the company moving forward.

Adoption of Financial Statements and Dividend Declaration

The meeting began with the formal adoption of the income statement and balance sheet for both BioArctic AB and its group, as detailed in the submitted accounting documents. Central to these discussions was the approval of a dividend of SEK 2 per share, with June 1, 2026, designated as the record date for this distribution to shareholders. This dividend reflects the company's ongoing commitment to delivering value to its investors.

Discharge from Liability

Another significant resolution involved discharging the board of directors and CEO from liability concerning their actions during the 2025 financial year. This step underscores the confidence in leadership accountability within the organization.

Board of Directors and Remuneration

The AGM also addressed the composition of the board. Continuity and fresh perspectives were balanced as existing members Eugen Steiner, Cecilia Edström, Anna-Lena Engwall, Lars Lannfelt, Lotta Ljungqvist, and Mikael Smedeby were re-elected. New appointments included Philip Scheltens and Linda Nilsson. Notably, Eugen Steiner was reaffirmed as the chairperson.

The meeting resolved to set the following remuneration for the directors: SEK 875,000 for the chairperson and SEK 315,000 for each of the other board members not employed by the company. Additional compensation was also established for roles in various committees reflecting their responsibilities, ensuring transparency and alignment with industry standards.

Auditor Appointment and Remuneration

Participants recognized the importance of independent oversight and re-elected the registered audit firm Öhrlings PricewaterhouseCoopers AB as the company's auditor. The auditor’s remuneration will be settled upon approved invoices, reinforcing accountability in financial practices.

Approval of the Remuneration Report

The AGM saw the approval of the remuneration report concerning the financial year 2025, laying the groundwork for continued transparency and governance.

Share Issuance Authorization

A pivotal measure passed was granting the board of directors the authority to issue new shares, warrants, and/or convertibles. This delegation allows the board to dynamically manage the company's capital strategy, enabling them to respond effectively to market opportunities while ensuring shareholder interests are kept in mind.

Incentive Program for Employees

In a bid to drive motivation among its employees, BioArctic introduced a new three-year incentive program encompassing a maximum of 235,000 performance-based share units (PSUs). The right to receive shares will depend on the fulfillment of various conditions including job tenure within the group and specified performance metrics that encourage alignment with the company’s objectives.

Updated Remuneration Guidelines for Senior Executives

The AGM resolved to update the guidelines for senior executive remuneration, emphasizing that extraordinary performances may justify additional variable compensation beyond standard target-based bonuses. This measure is aimed at fostering enhanced performance-driven culture within the company.

In summary, this year’s AGM reflects BioArctic’s commitment to strong governance practices, shareholder value enhancement, and strategic leadership. As the biopharma sector continues to evolve, the directives set forth in this meeting position BioArctic for sustained growth and innovation.

For further insights into BioArctic's direction and innovations in treatment for neurodegenerative diseases, visit BioArctic's website.